Argent BioPharma Ltd. Raised US$4,500,000
Argent BioPharma (ASX:RGT) (OTCQB:RGTLF) has successfully completed a US$4.5 million capital raise through a placement of 5,625,000 Units at US$0.80 each. Each Unit includes two ordinary shares and one warrant exercisable at US$0.55 with a three-year expiry.
The placement will be executed in two tranches: Tranche 1 with 5,000,000 shares and 2,500,000 warrants issued immediately, and Tranche 2 with 6,250,000 shares and 3,125,000 warrants subject to shareholder approval. The shares are priced at US$0.40, representing a 370% premium to the 15-day VWAP.
The funds will support Argent's drug development pipeline, particularly CannEpil® clinical studies. The company is conducting a strategic review following LSE delisting and preparing for US National Listing. Sputnik Enterprises , acting as corporate advisor, will receive a 5% cash fee and 1,125,000 warrants.
Argent BioPharma (ASX:RGT) (OTCQB:RGTLF) ha completato con successo un incremento di capitale di 4,5 milioni di dollari USA attraverso un collocamento di 5.625.000 Unità a 0,80 dollari ciascuna. Ogni Unità include due azioni ordinarie e un warrant esercitabile a 0,55 dollari con scadenza di tre anni.
Il collocamento sarà eseguito in due tranche: Tranche 1 con 5.000.000 azioni e 2.500.000 warrant emessi immediatamente, e Tranche 2 con 6.250.000 azioni e 3.125.000 warrant soggetti ad approvazione degli azionisti. Le azioni sono prezzate a 0,40 dollari, rappresentando un premio del 370% rispetto al VWAP di 15 giorni.
I fondi supporteranno il pipeline di sviluppo del farmaco di Argent, in particolare gli studi clinici di CannEpil®. L'azienda sta conducendo una revisione strategica a seguito della cancellazione dalla LSE e si sta preparando per una registrazione nazionale negli Stati Uniti. Sputnik Enterprises, in qualità di consulente aziendale, riceverà una commissione in contanti del 5% e 1.125.000 warrant.
Argent BioPharma (ASX:RGT) (OTCQB:RGTLF) ha completado con éxito una recapitalización de 4,5 millones de dólares estadounidenses a través de una colocación de 5.625.000 Unidades a 0,80 dólares cada una. Cada Unidad incluye dos acciones ordinarias y una garantía ejercitable a 0,55 dólares con un vencimiento de tres años.
La colocación se realizará en dos tramos: Tramo 1 con 5.000.000 acciones y 2.500.000 garantías emitidas de inmediato, y Tramo 2 con 6.250.000 acciones y 3.125.000 garantías sujetas a la aprobación de los accionistas. Las acciones están valoradas en 0,40 dólares, lo que representa una prima del 370% respecto al VWAP de 15 días.
Los fondos apoyarán la cartera de desarrollo de fármacos de Argent, en particular los estudios clínicos de CannEpil®. La empresa está llevando a cabo una revisión estratégica tras su deslisting de LSE y se está preparando para una cotización nacional en EE. UU. Sputnik Enterprises, actuando como asesor corporativo, recibirá un honorario en efectivo del 5% y 1.125.000 garantías.
Argent BioPharma (ASX:RGT) (OTCQB:RGTLF)는 450만 달러의 자본 조달을 0.80달러에 5,625,000 유닛을 배치하여 성공적으로 완료했습니다. 각 유닛에는 두 개의 보통주와 0.55달러에 행사 가능한 하나의 워런트가 포함되어 있으며, 만료는 3년입니다.
이번 배치는 두 트랜치로 이루어집니다: 트랜치 1은 5,000,000 주와 2,500,000 워런트가 즉시 발행되고, 트랜치 2는 주주 승인에 따라 6,250,000 주와 3,125,000 워런트를 발행합니다. 주가는 0.40달러로, 15일 VWAP보다 370%의 프리미엄을 나타냅니다.
자금은 Argent의 약물 개발 파이프라인, 특히 CannEpil®의 임상 연구를 지원할 것입니다. 회사는 LSE 상장 폐지 이후 전략적 검토를 수행 중이며, 미국 국가 상장을 준비하고 있습니다. 스푸트니크 엔터프라이즈는 기업 자문역할을 맡고 있으며, 5%의 현금 수수료와 1,125,000개의 워런트를 받을 예정입니다.
Argent BioPharma (ASX:RGT) (OTCQB:RGTLF) a réussi à réaliser une augmentation de capital de 4,5 millions de dollars US grâce à un placement de 5.625.000 unités à 0,80 dollar chacune. Chaque unité comprend deux actions ordinaires et un warrant exerçable à 0,55 dollar, avec une expiration de trois ans.
Le placement sera réalisé en deux tranches : Tranche 1 avec 5.000.000 actions et 2.500.000 warrants émis immédiatement, et Tranche 2 avec 6.250.000 actions et 3.125.000 warrants soumis à l'approbation des actionnaires. Les actions sont évaluées à 0,40 dollar, représentant une prime de 370 % par rapport au VWAP de 15 jours.
Les fonds soutiendront le pipeline de développement de médicaments d’Argent, en particulier les études cliniques de CannEpil®. L'entreprise effectue un examen stratégique suite à son retrait de la LSE et se prépare à un enregistrement national aux États-Unis. Sputnik Enterprises, agissant en tant que conseiller d'entreprise, recevra des frais en espèces de 5 % et 1.125.000 warrants.
Argent BioPharma (ASX:RGT) (OTCQB:RGTLF) hat erfolgreich eine Kapitalerhöhung in Höhe von 4,5 Millionen US-Dollar durch die Platzierung von 5.625.000 Einheiten zu je 0,80 US-Dollar abgeschlossen. Jede Einheit enthält zwei Stammaktien und einen Warrant, der für 0,55 US-Dollar mit einer Laufzeit von drei Jahren ausgeübt werden kann.
Die Platzierung erfolgt in zwei Tranchen: Tranche 1 mit 5.000.000 Aktien und 2.500.000 Warrants wird sofort ausgegeben, und Tranche 2 mit 6.250.000 Aktien und 3.125.000 Warrants unterliegt der Genehmigung der Aktionäre. Die Aktien sind mit 0,40 US-Dollar bewertet, was einen Aufschlag von 370 % auf den 15-Tage-VWAP darstellt.
Die Mittel unterstützen die Medikamentenentwicklungspipeline von Argent, insbesondere die klinischen Studien zu CannEpil®. Das Unternehmen führt nach der delisting von der LSE eine strategische Überprüfung durch und bereitet sich auf eine nationale Listung in den USA vor. Sputnik Enterprises, als Unternehmensberater, erhält eine Barvergütung von 5 % und 1.125.000 Warrants.
- Successful capital raise of US$4.5 million
- Share placement price represents 370% premium to 15-day VWAP
- Progress toward US National Listing
- Potential dilution from 11.25 million new shares and 6.75 million warrants
- Recent delisting from LSE
- Need for operational and administrative review indicates potential restructuring
The company announces the successful completion of a
The Placement will be conducted in two tranches: Tranche 1: 5,000,000 Placement Shares and 2,500,000 Warrants to be issued immediately, utilising the Company's existing placement capacity under ASX Listing Rules 7.1 and 7.1A. Tranche 2: 6,250,000 Placement Shares and 3,125,000 Warrants to be issued subject to shareholder approval at an upcoming general meeting.
The Placement Shares will be issued at a price of
The proceeds from the Placement will support the advancement of Argent BioPharma's drug development pipeline, with a particular focus on progressing CannEpil® and its planned clinical studies.
The Company is also conducting a comprehensive strategic review of its operational and administrative functions to ensure the long-term sustainability of its operations, which is following the delisting from the LSE and establishing the work-plan toward US National Listing.
Corporate Advisor: Sputnik Enterprises Ltd acted as the corporate advisor for the Placement and will receive: A cash fee of
Authorised for release by the board of directors, for further information please contact:
Argent BioPharma Roby Zomer CEO & Managing Director +61 8 6555 2950 | Argent BioPharma Rowan Harland Company Secretary +61 8 6555 2950
|
About Argent BioPharma
Argent BioPharma Limited (the "Company") (ASX: RGT);(OTCQB: RGTLF) is an innovative clinical-stage biopharmaceutical company specializing in neuroimmunology, developing advanced nano-medicines to address unmet medical needs in central nervous system (CNS) disorders and immune-related conditions. By leveraging cutting-edge technologies, including the Neuro-Immune Modulatory (NIM) System and its role in coordinating nervous and immune responses, Argent BioPharma's robust pipeline—featuring lead candidates like CannEpil®, CogniCann®, and CimetrA®—targets complex diseases where effective treatments are lacking. Through a commitment to science-driven innovation and patient-centered outcomes, Argent BioPharma is reshaping the future of care for chronic, inflammatory, and neurodegenerative diseases
Follow us through our social media channels:
LinkedIn: Argent BioPharma
Twitter: @ArgentBioPharma
Facebook: Argent BioPharma
View original content:https://www.prnewswire.com/news-releases/argent-biopharma-ltd-raised-us4-500-000--302344254.html
SOURCE Argent BioPharma Ltd.
FAQ
How much did Argent BioPharma (RGTLF) raise in its January 2025 placement?
What is the structure of RGTLF's January 2025 capital raising units?
What premium does RGTLF's placement price represent to its trading price?
How will RGTLF use the proceeds from its January 2025 placement?
What are the terms of RGTLF's corporate advisor compensation for the placement?
